Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2014 1
2019 2
2020 3
2021 1
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Calaspargase Pegol.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 35073033 Free Books & Documents. Review.
No information is available on the clinical use of calaspargase pegol during breastfeeding. Because calaspargase is a large protein molecule with a molecular weight of about 140,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partiall …
No information is available on the clinical use of calaspargase pegol during breastfeeding. Because calaspargase is a large pr …
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, Koch V, Kay-Green S, Athale UH, Clavell LA, Cole PD, Harris MH, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Place AE, Schorin MA, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Vrooman LM, et al. J Clin Oncol. 2021 Nov 1;39(31):3496-3505. doi: 10.1200/JCO.20.03692. Epub 2021 Jul 6. J Clin Oncol. 2021. PMID: 34228505 Clinical Trial.
PURPOSE: Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia (ALL) Consortium Protocol 11-001 assessed efficacy and toxicity of calaspargase pegol (calaspargase), a novel pegylated asparaginase formulation with longer half-life, compared with the standard form …
PURPOSE: Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia (ALL) Consortium Protocol 11-001 assessed efficacy and toxicity of cal …
Calaspargase Pegol (Asparlas): CADTH Reimbursement Recommendation: Indication: As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 to 21 years.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jan. Report No.: PC0321REC. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jan. Report No.: PC0321REC. PMID: 38564534 Free Books & Documents. Review.
FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults.
Li RJ, Jin R, Liu C, Cao X, Manning ML, Di XM, Przepiorka D, Namuswe F, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R. Li RJ, et al. Clin Cancer Res. 2020 Jan 15;26(2):328-331. doi: 10.1158/1078-0432.CCR-19-1255. Epub 2019 Aug 23. Clin Cancer Res. 2020. PMID: 31444252
On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (CALASP), an asparagine-specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age …
On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (CALASP), an asparagine-specific enzym …
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Keilani T, Lane AR, Loh ML, Reaman GH, Adamson PC, Wood B, Wood C, Zheng HW, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Angiolillo AL, et al. J Clin Oncol. 2014 Dec 1;32(34):3874-82. doi: 10.1200/JCO.2014.55.5763. Epub 2014 Oct 27. J Clin Oncol. 2014. PMID: 25348002 Free PMC article. Clinical Trial.
Pegaspargase (SS-PEG), a pegylated form of Escherichia coli L-asparaginase with a succinimidyl succinate (SS) linker, is the first-line asparaginase product used in Children's Oncology Group (COG) ALL trials. Calaspargase pegol (SC-PEG) replaces the SS linker in SS- …
Pegaspargase (SS-PEG), a pegylated form of Escherichia coli L-asparaginase with a succinimidyl succinate (SS) linker, is the first-line aspa …
Space for Calaspargase? A New Asparaginase for Acute Lymphoblastic Leukemia.
Lew G. Lew G. Clin Cancer Res. 2020 Jan 15;26(2):325-327. doi: 10.1158/1078-0432.CCR-19-2975. Epub 2019 Oct 22. Clin Cancer Res. 2020. PMID: 31641006
In December 2018, the FDA approved calaspargase pegol-mknl (Asperlas, Servier Pharmaceuticals) for acute lymphoblastic leukemia (ALL) in children and young adults up to age 21. ...
In December 2018, the FDA approved calaspargase pegol-mknl (Asperlas, Servier Pharmaceuticals) for acute lymphoblastic leukemi …
Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
Feldman K, Aaronson K, Gu T, Ige K, Southworth E, Sanchez L, Stieglitz E. Feldman K, et al. Pediatr Blood Cancer. 2024 Apr;71(4):e30891. doi: 10.1002/pbc.30891. Epub 2024 Feb 4. Pediatr Blood Cancer. 2024. PMID: 38311802
RESULTS: We identified 11 patients who underwent a total of 33 desensitizations to pegaspargase and calaspargase pegol-mknl. No patients experienced clinically significant hypersensitivity reactions necessitating stopping the infusion, nor administration of rescue m …
RESULTS: We identified 11 patients who underwent a total of 33 desensitizations to pegaspargase and calaspargase pegol-mknl. N …
Improving the Treatment of Acute Lymphoblastic Leukemia.
Radadiya A, Zhu W, Coricello A, Alcaro S, Richards NGJ. Radadiya A, et al. Biochemistry. 2020 Sep 8;59(35):3193-3200. doi: 10.1021/acs.biochem.0c00354. Epub 2020 Aug 23. Biochemistry. 2020. PMID: 32786406 Free PMC article.